Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEPLID: Lidocaine for Prevention of Post-ERCP Pancreatitis
NCT05667987Recruiting
- Sponsor
- Ramsay Santé
- Start
- Jan 2024
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, single-blind trial of Lidocaine Hydrochloride Injection, without epinephrine in post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP) (2 arms), sponsored by Ramsay Santé. Primary endpoint: Plasma lipase level at 24 hours. Started Jan 2024; status: recruiting.
02
Drugs
Lidocaine Hydrochloride Injection, without epinephrine
03
Conditions
post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP)
Beyond the preview
Go deeper on NCT05667987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05667987.